This article is available to subscribers. Subscribe now. Already have an account? Sign in

EditorialFree Preview

New Decongestion Strategies in an Evolving Heart Failure Landscape

List of authors.
  • G. Michael Felker, M.D.

Hospitalization for heart failure, usually due to volume overload, is among the most common reasons for hospitalization worldwide, and decongestion with loop diuretics is the primary focus of treatment in most patients.1 Despite the ubiquity of this clinical scenario in daily practice, high-quality data from randomized trials evaluating effective treatment approaches are sparse.2 The Diuretic Optimization Strategies Evaluation (DOSE) trial, published more than 11 years ago, compared strategies regarding dose level (high- vs. low-intensity loop diuretics) and means of administration (bolus vs. continuous infusion) in patients hospitalized with heart failure and congestion.3 Despite its modest size, that trial represented an . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.

This editorial was published on August 27, 2022, at NEJM.org.

Author Affiliations

From the Duke University School of Medicine and Duke Clinical Research Institute, Durham, NC.